KT-333 is under clinical development by Kymera Therapeutics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KT-333’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KT-333 overview
KT-333 is under development for the treatment of peripheral T cell lymphoma (PTCL), cutaneous T cell lymphoma (CTCL), large granular lymphocytic leukemia (LGL-L), Hodgkin lymphoma, small lymphocytic lymphoma (SLL), non-Hodgkin Lymphoma, natural killer cell lymphomas, T-cell lymphomas and solid tumors like colorectal cancer, non-small cell lung cancer, bile duct cancer (cholangiocarcinoma), kidney cancer (renal cell cancer), head and neck cancer and alcohol use disorder. It is administered through intravenous route. The drug candidate is a heterobifunctional PROTAC (proteolysis targeting chimera) which acts by degrading STAT3. It is developed based on Pegasus platform.
Kymera Therapeutics overview
Kymera Therapeutics (Kymera) is a biopharmaceutical company that discovers and develops small molecule therapeutics for protein degradation. The company’s pipeline includes IRAK4 for the treatment of atopic dermatitis, hidradenitis suppurativa, macrophage activation syndrome, general pustular psoriasis and rheumatoid arthritis, IRAKIMiD for the treatment of MYD88 tumor, STAT3 for PTCL, LGL-L, CTCL and Solid Tumors. Kymera’s other pipeline includes MDM2 for Liquid and Solid Tumors. The company also utilizes Pegasus a drug discovery platform that allows the discovery of selective small molecule protein degraders against disease-causing proteins throughout the body. Kymera is headquartered in Watertown, Massachusetts, the US.
For a complete picture of KT-333’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
